AU2019335203B2 - Methods of treating mycobacterial infections using tetracycline compounds - Google Patents

Methods of treating mycobacterial infections using tetracycline compounds Download PDF

Info

Publication number
AU2019335203B2
AU2019335203B2 AU2019335203A AU2019335203A AU2019335203B2 AU 2019335203 B2 AU2019335203 B2 AU 2019335203B2 AU 2019335203 A AU2019335203 A AU 2019335203A AU 2019335203 A AU2019335203 A AU 2019335203A AU 2019335203 B2 AU2019335203 B2 AU 2019335203B2
Authority
AU
Australia
Prior art keywords
methods
tetracycline compounds
mycobacterial infections
treating mycobacterial
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019335203A
Other languages
English (en)
Other versions
AU2019335203A1 (en
Inventor
Michael Henry Cynamon
Michael P. Draper
Judith N. Steenbergen
S. Ken Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paratek Pharmaceuticals Inc
US Department of Veterans Affairs
Original Assignee
Paratek Pharmaceuticals Inc
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals Inc, US Department of Veterans Affairs filed Critical Paratek Pharmaceuticals Inc
Publication of AU2019335203A1 publication Critical patent/AU2019335203A1/en
Application granted granted Critical
Publication of AU2019335203B2 publication Critical patent/AU2019335203B2/en
Priority to AU2025234215A priority Critical patent/AU2025234215A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2019335203A 2018-09-04 2019-09-03 Methods of treating mycobacterial infections using tetracycline compounds Active AU2019335203B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025234215A AU2025234215A1 (en) 2018-09-04 2025-09-18 Methods of treating mycobacterial infections using tetracycline compounds

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862726738P 2018-09-04 2018-09-04
US62/726,738 2018-09-04
US201862731410P 2018-09-14 2018-09-14
US62/731,410 2018-09-14
US201862746039P 2018-10-16 2018-10-16
US62/746,039 2018-10-16
US201862760131P 2018-11-13 2018-11-13
US62/760,131 2018-11-13
PCT/US2019/049368 WO2020051151A1 (en) 2018-09-04 2019-09-03 Methods of treating mycobacterial infections using tetracycline compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025234215A Division AU2025234215A1 (en) 2018-09-04 2025-09-18 Methods of treating mycobacterial infections using tetracycline compounds

Publications (2)

Publication Number Publication Date
AU2019335203A1 AU2019335203A1 (en) 2021-05-06
AU2019335203B2 true AU2019335203B2 (en) 2025-06-19

Family

ID=69722600

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019335203A Active AU2019335203B2 (en) 2018-09-04 2019-09-03 Methods of treating mycobacterial infections using tetracycline compounds
AU2025234215A Pending AU2025234215A1 (en) 2018-09-04 2025-09-18 Methods of treating mycobacterial infections using tetracycline compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025234215A Pending AU2025234215A1 (en) 2018-09-04 2025-09-18 Methods of treating mycobacterial infections using tetracycline compounds

Country Status (13)

Country Link
US (2) US12161655B2 (https=)
EP (1) EP3846805A4 (https=)
JP (2) JP7466544B2 (https=)
KR (2) KR20260036400A (https=)
CN (1) CN113164456A (https=)
AU (2) AU2019335203B2 (https=)
BR (1) BR112021004057A2 (https=)
CA (1) CA3111447A1 (https=)
MA (1) MA53564A (https=)
MX (2) MX2021002503A (https=)
PH (1) PH12021550452A1 (https=)
SG (1) SG11202102149SA (https=)
WO (1) WO2020051151A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7840880B2 (ja) * 2020-06-11 2026-04-06 パラテック ファーマシューティカルズ，インコーポレイテッド オマダサイクリンの結晶形態、その合成方法及びその使用方法
TW202237116A (zh) * 2020-12-02 2022-10-01 日商塩野義製藥股份有限公司 以組合細胞色素bc1抑制劑與克拉黴素或阿奇黴素為特徵之用於治療分枝桿菌感染之藥物
JP2024511419A (ja) * 2021-03-24 2024-03-13 インスメッド インコーポレイテッド 非結核性抗酸菌肺疾患を治療するための併用療法
WO2025221846A1 (en) * 2024-04-18 2025-10-23 St. Jude Children's Research Hospital, Inc. Compositions and methods for treating non-tuberculosis mycobacteria infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846939B2 (en) * 2000-07-07 2005-01-25 Paratek Pharmaceuticals, Inc. 9-substituted minocycline compounds
US9314475B2 (en) * 2008-03-28 2016-04-19 Paratek Pharmaceuticals, Inc. Oral and injectable formulations of tetracycline compounds
WO2018051102A1 (en) * 2016-09-15 2018-03-22 Antibiotx A/S Combinations comprising dibromopropamidine or diminazene and a tetracycline anti-bacterial agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP2311451A1 (en) 2002-03-08 2011-04-20 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
TWI680117B (zh) 2008-05-19 2019-12-21 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
KR101732084B1 (ko) 2011-07-26 2017-05-02 케이비피 바이오사이언시즈 씨오., 엘티디. 9-아미노메틸 치환된 테트라사이클린 화합물
JP2015527403A (ja) 2012-09-11 2015-09-17 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖプロテアーゼ阻害剤
CA3018872A1 (en) * 2016-03-24 2017-09-28 Paratek Pharmaceuticals, Inc. Methods of treating a bacterial infection in a subject at risk of developing c. difficile infection
JP2019514952A (ja) * 2016-05-02 2019-06-06 パラテック ファーマシューティカルズ，インコーポレイテッド ９−アミノメチルミノサイクリン化合物及び尿路感染症（ｕｔｉ）の処置におけるその使用方法
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846939B2 (en) * 2000-07-07 2005-01-25 Paratek Pharmaceuticals, Inc. 9-substituted minocycline compounds
US9314475B2 (en) * 2008-03-28 2016-04-19 Paratek Pharmaceuticals, Inc. Oral and injectable formulations of tetracycline compounds
WO2018051102A1 (en) * 2016-09-15 2018-03-22 Antibiotx A/S Combinations comprising dibromopropamidine or diminazene and a tetracycline anti-bacterial agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WALLACE RICHARD J. ET AL, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 46, no. 10, 1 October 2002 (2002-10-01), US, pages 3164 - 3167, XP055942573, ISSN: 0066-4804 *

Also Published As

Publication number Publication date
JP2021536504A (ja) 2021-12-27
US20210346408A1 (en) 2021-11-11
EP3846805A1 (en) 2021-07-14
CN113164456A (zh) 2021-07-23
US20250332178A1 (en) 2025-10-30
US12161655B2 (en) 2024-12-10
MX2021002503A (es) 2021-06-15
AU2025234215A1 (en) 2025-10-16
KR20260036400A (ko) 2026-03-16
KR102933150B1 (ko) 2026-03-03
BR112021004057A2 (pt) 2021-05-25
EP3846805A4 (en) 2022-08-24
MA53564A (fr) 2021-07-14
WO2020051151A1 (en) 2020-03-12
SG11202102149SA (en) 2021-04-29
PH12021550452A1 (en) 2021-12-06
MX2024008671A (es) 2024-07-23
JP2024084794A (ja) 2024-06-25
CA3111447A1 (en) 2020-03-12
KR20210090160A (ko) 2021-07-19
AU2019335203A1 (en) 2021-05-06
JP7466544B2 (ja) 2024-04-12

Similar Documents

Publication Publication Date Title
EP4412664A4 (en) Endoscopic device for the treatment of infections
AU2019335203B2 (en) Methods of treating mycobacterial infections using tetracycline compounds
EP3886853A4 (en) DIARYLHYDANTOI COMPOUNDS AND METHODS OF USE THEREOF
EP3863656A4 (en) Methods of treatment of inflammatory conditions and associated infections
EP3897642A4 (en) METHODS OF TREATMENT OF INFLAMMATION
EP3426671A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
PT3565551T (pt) Métodos de tratamento de infeções bacterianas com uma combinação de vaborbactam e meropenem
EP3856241A4 (en) TREATMENT PROCESSES
EP3778916A4 (en) PROCEDURE FOR ANTIGEN TREATMENT
HK40046596A (en) Methods of treating mycobacterial infections using tetracycline compounds
ZA201901948B (en) Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections
EP3884944A4 (en) USE OF CHIDAMID
HK40051024A (en) Methods of treating bacterial infections with minocycline
HK40036490A (en) Methods of treating bacterial infections
HK40086190B (en) Treating & preventing microbial infections
HK40086190A (en) Treating & preventing microbial infections
HK40066686A (en) Methods of treating multiple sclerosis
HK40062182A (en) Method of treatment
HK40048047A (en) Treatment of pneumonia
HK40074183A (en) Methods of treating cryptococcus infections
HK40026676A (en) Compounds and methods for treating bacterial infections
HK40067683A (en) Methods for the treatment of beta-thalassemia
HK40075476A (en) Methods of treatment
HK40061099A (en) Methods of treating follicular lymphoma
AU2017902918A0 (en) Treatment of infections (1)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)